Hongene Biotech is a producer of RNA building blocks – the first step for what’s possible in RNA drug-discovery and development. David Butler, Ph.D., Chief Technology Officer of Hongene, joins the Patient Empowerment Program to discuss why Hongene aims to help make RNA medicines accessible and affordable for patients everywhere, regardless of prevalence.

Survey – Patient Empowerment Program Podcast

Register for the 2024 Nano-rare Patient Colloquium

Hongene website

Make Hope Possible with a Donation

• 2:40 Hongene Biotech and what do they do
• 8:09 The early days of nucleoside building blocks and maturation of Hongene
• 12:00 Hongene is a strong supporter of n-Lorem. Why? 15:30 David’s origins in the chemistry field
• 17:38 Incremental progress that has been made in science and manufacturing

David Butler is the Chief Technology Officer at Hongene Biotech. David has nearly two decades of experience in the oligonucleotide field. Prior to joining Hongene in 2023, he led organizations driving drug discovery and development of oligonucleotide therapeutics, most recently as Head of Chemistry at Korro Bio, Head of Therapeutics Development at Altrna, and Head of Medicinal Chemistry at Wave Life Sciences. He began his career in oligonucleotides as a Principal Scientist at Alnylam Pharmaceuticals in 2007 developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA related products today. He holds a PhD in Chemistry from the University of St Andrews, and is passionate about working with individuals and companies to help them succeed.

We cannot do
this alone

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.